Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Explore this paper's citation graph
Summary
Sunitinib demonstrates longer overall survival compared with IFN-α plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC, highlighting an improved prognosis in patients with RCC in the era of targeted therapy.
- Type
- article
- Published
- 2009-08-01
- Cited by
- 2,202
- References
- 14
- OpenAlex
- https://openalex.org/W2099088585
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:7675933
Keywords
Medicine, Sunitinib, Renal cell carcinoma, Internal medicine, Hazard ratio
References
- [New guidelines to evaluate the response to treatment in solid tumors].
- Sunitinib efficacy against advanced renal cell carcinoma.
- PCN72 HEALTH-RELATED QUALITY OF LIFE (HRQOL)AND KIDNEY CANCER-RELATED SYMPTOMS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)TREATED WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA IN A RANDOMISED, MULTINATIONAL PHASE III TRIAL: RESULTS FOR EUROPEAN AND US SUBSAMPLE ANALYSES
- Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
- Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
- Sunitinib in patients with metastatic renal cell carcinoma.
- Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
- Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
- Sunitinib: from rational design to clinical efficacy.
- Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC)
- Modelling Survival Data in Medical Research.
- Modelling Survival Data in Medical Research
- Modelling Survival Data in Medical Research
Cited by
- Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy
- [Management of side effects of targeted therapies in renal cancer: cutaneous side effects].
- Past, present and future of targeted therapy in solid tumors.
- Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
- Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
- Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma
- Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
- Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial
- Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation
- Cardiovascular toxicities of biological therapies.
- Systemic cancer therapy: achievements and challenges that lie ahead
- Differential microRNA expression in renal cell carcinoma
- Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
- The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ
- Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma
- Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors
- Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK
- Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT
- Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents
- The complexity of sunitinib dosing in renal cell cancer patients
Related papers
- Ischaemic stroke in a patient on sunitinib
- Improvement of Psoriasis During Sunitinib Therapy for Renal Cell Carcinoma
- Sunitinib as a molecular targeting agent in renal cell carcinoma
- Sunitinib Associated Per Rectal Bleeding in a Patient with Metastatic Renal Cell Carcinoma-A Case Report
- PCN135 IMPROVEMENT IN QUALITY OF LIFE OUTCOMES IN INTERFERONALPHA TREATED PATIENTS COMPARED TO SUNITINIB IN ADVANCE OR METASTATIC RENAL CELL CARCINOMA
- 11C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma
- Very Late Recurrence of Renal Cell Carcinoma Experiencing Long-term Response to Sunitinib: A Case Report
- Sunitinib in renal-cell carcinoma: expanded indications.
- Closer Monitoring of Patients Treated with Sunitinib for Advanced Renal Cancer